Work

Concomitant Enalapril and Spironolactone-Induced Hyperkalemia in a Pediatric Patient.

Year: 2026

Type: article

Abstract: Spironolactone is a mineralocorticoid receptor antagonist with potassium-sparing effects used in the management of heart failure to minimize morbidity and mortality. It is typically given in combination with an angiotensin-converting enzyme inhibitor (ACEI) as part of standard management of pediatric heart failure but has limited literature regarding safety and efficacy in this population. We report a case of probable concomitant enalapril and spironolactone-induced hyperkalemia in a 2-month old female. The patient presented with Class III congestive heart failure and was initiated on enalapril and spironolactone. New hyperkalemia (serum potassium concentration 8.9 mEq/L) developed on day 7 after initiation and persisted despite decreases in the spironolactone dose. Persistent hyperkalemia and hyponatremia with a metabolic acidosis led to the discontinuation of spironolactone by day 12 of admission. The hyperkalemia resolved within 72 hours of discontinuation without further interventions. Based on our patient's course, hyperkalemia in a pediatric patient may occur when spironolactone and an ACEI are given concomitantly and resolve upon discontinuation of spironolactone.

Source: PubMed

DOI: 10.5863/jppt-25-00009

Authors: Sarah Mae Rogado, Jamie M Pinto, Liliana Cruz Hernandez, Stephanie Chin, Anita Siu

Institutions: Jersey Shore University Medical Center, Hackensack Meridian School of Medicine, New York University, Rutgers, The State University of New Jersey

Language: English

Topic: Potassium and Related Disorders

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7128727694

FWCI:

Cites:

Cited by:

Related to: